
The goal of team VPE is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at an unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development. In partnership with Sanofi, the VPE team will develop innovative artificial intelligence methods to build the virtual patient platform. As a proof-of-concept, the initial platform will focus on chronic immune-mediated diseases such as atopic dermatitis (AD) and inflammatory bowel disease (IBD), where new medication that can address patient heterogeneity is needed.
Mentors
- Dr. Tommaso Andreani (Industry Mentor)
Sr. Principal Data Scientist – Disease Modeling Innovation Lead, Sanofi
- Dr. Jan Korbel (Academic Mentor)
Head of Data Science, European Molecular Biology Laboratory
Publications
- Gurdeep Singh, Lilija Wehling, Ahmad Wisnu Mulyadi, Rakesh Hadne Sreenath, Douglas McCloskey (BioMed X Institute), Thomas Klabunde, Tommaso Andreani (Sanofi) (2025)
TALK2BIOMODELS AND TALK2KNOWLEDGEGRAPHS: AI AGENT-BASED APPLICATION FOR PREDICTION OF PATIENT BIOMARKERS AND REASONING OVER BIOMEDICAL KNOWLEDGE GRAPHS
MLGenX 2025, ICLR Conference Workshop Paper
You can also find us on GitHub

The research of this team is kindly supported by Sanofi.